Skip to main content
. 2021 Nov 10;8:753313. doi: 10.3389/fcvm.2021.753313

Figure 1.

Figure 1

CTRCD biomarkers. Classic biomarkers include Tn and BNP, which mainly reflect cardiac injury. Emerging biomarkers include MPO, GDF-15, CRP, ST2, PlGF, galectin-3 and miRNAs. They can reflect various aspects of the pathophysiology of the heart after cancer treatment, such as oxidative stress, inflammation and fibrosis.